重组人血管内皮抑素联合同步放化疗治疗晚期非小细胞肺癌临床研究

Clinical Research on the Treatment of Non-small-cell Carcinoma by Recombinant Human Endostatin and Synchronous Chemoradiotherapy

目的:探讨重组人血管内皮抑素联合同步化疗治疗晚期非小细胞肺癌(NSCLC)的临床疗效。方法:将我院收治的40例NSCLC患者随机分为治疗组和对照组,对照组患者采用紫杉醇化疗方案联合同步放射治疗,治疗组患者给予重组人血管内皮抑素联合同步放化疗进行治疗,治疗2个周期后对患者的近期疗效、毒副反应以及无肿瘤进展时间(TTP)等进行比较。结果:治疗组CR+PR的患者为15例,明显高于对照组的5例(P<0.05);治疗组患者TTP为154±11d,中位生存时间为274d,而对照组TTP为108±8d,中位生存时间为179d,两组患者比较存在明显的差异性(P<0.05);治疗组患者QOL评分明显优于对照组(P<0.05),而两组患者毒副反应无明显的差异性(P>0.05)。结论:对晚期NSCLC患者采用重组人血管内皮抑素联合同步化疗进行治疗,可提高患者生存时间,且不会增加患者毒副反应的发生。

Objective： To investigate the clinical efficacy of recombinant human endostatin with synchronous chemoradiotherapy on advanced non-small cell lung cancer（NSCLC）.Methods： 40 cases of NSCLC patients in our hospital were randomly divided into treatment group and control group.The control group was treated with taxol regimen combined with concurrent radiation therapy,and the treatment group was given recombinant human endostatin combined with concurrent chemoradiotherapy.After two treating cycles,the recent efficacy,toxicity and no tumor time to progression（TTP）were compared between the two groups.Results： There were 15 cases of CR ＋ PR patients in the treatment group,significantly higher than that in the control group which had 5 cases（P0.05）;The TTP was（154 ±11） d,and the median survival time was 274d in treatment group,but were respectively TTP was（108± 8）d,and 179d in the control group,both with significant differences between the two groups（P0.05）.The QOL score in the treatment group was significantly better than the control group（P0.05）,but there was no significant difference（P0.05） in toxicity between two groups.Conclusion： The recombinant human endostatin with synchronous chemoradiotherapy can increase the survival time of patients with advanced NSCLC but did not increase the toxicity effect on patients.